Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Approximately 200,000 multiple sclerosis (MS) patients worldwide receive B-cell-depleting immunotherapy with rituximab (anti-CD20), which eliminates the ability to generate an antibody response to new infections. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies might help viral clearance, these patients could be at risk of severe complications if infected. Here, we report on an MS patient who had received rituximab for ~3 years. The patient was examined 5 days before the onset of coronavirus disease 2019 (COVID-19) symptoms and was admitted to the hospital 2 days after. She recovered 14 days after symptom onset despite having a 0% B lymphocyte count and not developing SARS-CoV-2 immunoglobulin G (IgG) antibodies.

Original publication

DOI

10.1177/1352458520943791

Type

Journal article

Journal

Mult Scler

Publication Date

09/2020

Volume

26

Pages

1261 - 1264

Keywords

B-cell-depleting therapy, COVID-19, Multiple sclerosis (MS), SARS-CoV-2 antibodies, cellular immune responses, rituximab, B-Lymphocytes, Betacoronavirus, CD4-CD8 Ratio, CD4-Positive T-Lymphocytes, Coronavirus Infections, Disease Progression, Female, Humans, Immunity, Cellular, Killer Cells, Natural, Lymphocyte Count, Middle Aged, Multiple Sclerosis, Chronic Progressive, Pandemics, Pneumonia, Viral, Rituximab